GlassScriptPhysician profile
Robert N Montgomery
NPI 1124064167
$9,685.30
in general payments reported to CMS, 2019-2025
56 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,755 · 2020: $589 · 2021: $1,223 · 2022: $1,638 · 2023: $1,394 · 2024: $1,609 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,480.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,096.90 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $945.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $924.25 | 2019-2025 | |
| Abbvie INC. | $658.25 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $610.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $605.42 | 2022-2025 | Freestyle Libre 3, Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.00 | 2019-2024 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $554.15 | 2019-2025 | |
| Lilly USA, LLC | $414.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $355.00 | 2019-2025 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $291.12 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $226.22 | 2019-2022 | |
| Glaxosmithkline, LLC. | $192.93 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $179.82 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $169.08 | 2021-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.